+

WO2000071520A3 - Compositions pharmaceutiques et methodes d'utilisation - Google Patents

Compositions pharmaceutiques et methodes d'utilisation Download PDF

Info

Publication number
WO2000071520A3
WO2000071520A3 PCT/US2000/011256 US0011256W WO0071520A3 WO 2000071520 A3 WO2000071520 A3 WO 2000071520A3 US 0011256 W US0011256 W US 0011256W WO 0071520 A3 WO0071520 A3 WO 0071520A3
Authority
WO
WIPO (PCT)
Prior art keywords
aryl substituted
cholinergic receptors
nicotinic cholinergic
substituted alkylamines
activating nicotinic
Prior art date
Application number
PCT/US2000/011256
Other languages
English (en)
Other versions
WO2000071520A2 (fr
Inventor
Gary Maurice Dull
Erin E Reich
Jared Miller Wagner
Balwinder Singh Bhatti
Michael B Consilvio
Original Assignee
Targacept Inc
Gary Maurice Dull
Erin E Reich
Jared Miller Wagner
Balwinder Singh Bhatti
Michael B Consilvio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/317,327 external-priority patent/US20010031771A1/en
Application filed by Targacept Inc, Gary Maurice Dull, Erin E Reich, Jared Miller Wagner, Balwinder Singh Bhatti, Michael B Consilvio filed Critical Targacept Inc
Priority to JP2000619777A priority Critical patent/JP2003500393A/ja
Priority to KR1020017015045A priority patent/KR20020010670A/ko
Priority to BR0011534-7A priority patent/BR0011534A/pt
Priority to AU46678/00A priority patent/AU4667800A/en
Priority to MXPA01012202A priority patent/MXPA01012202A/es
Priority to CA002373789A priority patent/CA2373789A1/fr
Priority to EP00928437A priority patent/EP1185513A2/fr
Publication of WO2000071520A2 publication Critical patent/WO2000071520A2/fr
Publication of WO2000071520A3 publication Critical patent/WO2000071520A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Des patients susceptibles de souffrir ou souffrant de pathologies ou de troubles, tel que les troubles du système nerveux central, sont traités par l'administration d'aryloxyalkylamines et d'arylthioalkylamines, comprenant des pyridyloxylalkylamines, des phénoxyalkylamines, des pyridylthiolalkylamines et des phénylthiolalkylamines.
PCT/US2000/011256 1999-05-24 2000-04-27 Compositions pharmaceutiques et methodes d'utilisation WO2000071520A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000619777A JP2003500393A (ja) 1999-05-24 2000-04-27 薬学的組成物およびその使用
KR1020017015045A KR20020010670A (ko) 1999-05-24 2000-04-27 니코틴 콜린성 수용체를 활성화시킬 수 있는 아릴치환된알킬아민
BR0011534-7A BR0011534A (pt) 1999-05-24 2000-04-27 Alquilaminas aril substituìdas capazes de ativação de receptores colinérgicos nicotìnicos
AU46678/00A AU4667800A (en) 1999-05-24 2000-04-27 Pharmaceutical compositions and methods for use
MXPA01012202A MXPA01012202A (es) 1999-05-24 2000-04-27 Composiciones farmaceuticas y metodos de uso.
CA002373789A CA2373789A1 (fr) 1999-05-24 2000-04-27 Compositions pharmaceutiques et methodes d'utilisation
EP00928437A EP1185513A2 (fr) 1999-05-24 2000-04-27 Compositions pharmaceutiques et methodes d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/317,327 US20010031771A1 (en) 1999-05-24 1999-05-24 Pharmaceutical compositions and methods for use
US09/317,327 1999-05-24
US32714999A 1999-06-07 1999-06-07
US09/327,149 1999-06-07

Publications (2)

Publication Number Publication Date
WO2000071520A2 WO2000071520A2 (fr) 2000-11-30
WO2000071520A3 true WO2000071520A3 (fr) 2001-08-23

Family

ID=26980897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011256 WO2000071520A2 (fr) 1999-05-24 2000-04-27 Compositions pharmaceutiques et methodes d'utilisation

Country Status (8)

Country Link
EP (1) EP1185513A2 (fr)
JP (1) JP2003500393A (fr)
KR (1) KR20020010670A (fr)
AU (1) AU4667800A (fr)
BR (1) BR0011534A (fr)
CA (1) CA2373789A1 (fr)
MX (1) MXPA01012202A (fr)
WO (1) WO2000071520A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956786A1 (de) * 1999-11-25 2001-05-31 Basf Ag Verfahren zur Herstellung optisch aktiver Amine
US20010034357A1 (en) * 2000-02-02 2001-10-25 Nan-Horng Lin Substituted pyridine compounds useful for controlling chemical synaptic transmission
US6656958B2 (en) 2000-02-02 2003-12-02 Abbott Laboratories Substituted pyridine compounds useful for controlling chemical synaptic transmission
HUP0501017A3 (en) 2001-12-14 2010-06-28 Targacept Methods and compositions for treatment of central nervous system disorders
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2006015279A1 (fr) * 2004-07-28 2006-02-09 Neurogen Corporation Composés de diamine hétérocyclique comme liants du récepteur d'hormone concentrant de la mélamine, utile pour le traitement de l'obésité, du diabète et des troubles sexuels et de l'alimentation
KR100743617B1 (ko) * 2005-08-25 2007-07-27 주식회사 알에스텍 고광학순도를 갖는 키랄 3-히드록시 피롤리딘 및 그유도체를 제조하는 방법
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
EP2280010B1 (fr) * 2007-11-21 2012-12-19 Abbott Laboratories Dérivés d'alcane azabicyclique à substitution biaryle en tant que modulateurs de l'activité du récepteur nicotinique de l'acétylcholine dérivés d'alcanes azabicycliques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264466A (ja) * 1986-12-05 1988-11-01 Tooa Eiyoo Kk 新規フエノキシアルキルアミン誘導体及びその製造法
US5885998A (en) * 1995-01-06 1999-03-23 Bencherif; Merouane Methods for prevention and treatment of attention deficit disorder
WO1999051216A2 (fr) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Preparations pharmaceutiques et leur modes d'utilisation
WO2000062767A2 (fr) * 1999-04-20 2000-10-26 Targacept, Inc. Compositions pharmaceutiques permettant d'inhiber la production et la secretion de cytokine
WO2000075110A1 (fr) * 1999-06-07 2000-12-14 Targacept, Inc. Compositions pharmaceutiques et methodes d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264466A (ja) * 1986-12-05 1988-11-01 Tooa Eiyoo Kk 新規フエノキシアルキルアミン誘導体及びその製造法
US5885998A (en) * 1995-01-06 1999-03-23 Bencherif; Merouane Methods for prevention and treatment of attention deficit disorder
WO1999051216A2 (fr) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Preparations pharmaceutiques et leur modes d'utilisation
WO2000062767A2 (fr) * 1999-04-20 2000-10-26 Targacept, Inc. Compositions pharmaceutiques permettant d'inhiber la production et la secretion de cytokine
WO2000075110A1 (fr) * 1999-06-07 2000-12-14 Targacept, Inc. Compositions pharmaceutiques et methodes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NARITA, SENICHI ET AL: "Preparation of phenoxyalkylaminoalkylbenzothia- or oxazoles for treatment of circulatory disorders", XP002158326, retrieved from STN Database accession no. 111:7381 *
GUTHRIE R W ET AL: "PENTADIENYL CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF PLATELET-ACTIVATING FACTOR", JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 32, no. 8, 1989, pages 1820 - 1835, XP002037072, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives

Also Published As

Publication number Publication date
WO2000071520A2 (fr) 2000-11-30
MXPA01012202A (es) 2002-06-21
KR20020010670A (ko) 2002-02-04
JP2003500393A (ja) 2003-01-07
EP1185513A2 (fr) 2002-03-13
BR0011534A (pt) 2002-02-26
AU4667800A (en) 2000-12-12
CA2373789A1 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
AP1655A (en) A method of preparing quinazoline derivatives useful as anti-cancer compounds.
PT1147110E (pt) Derivados de pirazino (aza)-indol
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
MY107157A (en) Quinuclidine derivatives.
AP9701041A0 (en) Pyridylpyrrole compounds.
NO20002702L (no) Tienopyrimidiner
WO2000071520A3 (fr) Compositions pharmaceutiques et methodes d'utilisation
IL192287A0 (en) Pharmaceutical compositions and methods for use
GEP20053617B (en) Bridged Piperazine Derivatives
WO2002007678A3 (fr) Conopeptides $g(m)
HRP20010969B1 (en) Novel piperazinylalkylthiopyrimidine derivatives,
WO1999004770A3 (fr) Composition pharmaceutique active dans la reduction de production de proteine mcp-1
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
DK1025101T3 (da) Naphtho-imidazo[1,2-a]pyridinderivater, deres fremstilling og deres anvendelse ved behandlingen af sygdomme i centralnervesystemet
WO2001007431A3 (fr) Derives de benzothiophene
EP0495998A4 (fr)
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
WO1999051216A3 (fr) Preparations pharmaceutiques et leur modes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2373789

Country of ref document: CA

Ref country code: CA

Ref document number: 2373789

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 46678/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020017015045

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 619777

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012202

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000928437

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017015045

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000928437

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000928437

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017015045

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载